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bon receptor (AHR) accumulate retinyl palmitate, retinol
Increasing dietary ingestion of retinol and its esters does not and retinoic acid. This suggests a direct connection between result in a proportional increase in RA concentration, but the AHR and retinoid homeostasis. Retinoids control gene rather leads to accumulation of retinyl esters in liver tissue. It expression through the nuclear retinoic acid receptors should, therefore, be emphasized that direct administration (RARs) α, β and γ and 9-cis-retinoic acid recepof RA may be required for effective chemoprevention or tors α, β and γ, which bind with high affinity the natural differentiation therapy. ligands all-trans-retinoic acid and 9-cis-retinoic acid, respectively. Retinoids are effective chemopreventive agents against skin, head and neck, breast, liver and other forms Retinoid-binding proteins of cancer. Differentiation therapy of acute promyelocytic Retinoids travel in the blood and within different cellular leukemia (APL) is based on the ability of retinoic acid to compartments as non-covalent complexes with various proinduce differentiation of leukemic promyelocytes. Patients teins. The prototype retinoid-binding protein is the blood with relapsed, retinoid-resistant APL are now being treated retinol carrier, 21 kDa retinol-binding protein (RBP) ( Figure 1 ). with arsenic oxide, which results in apoptosis of the leu-
The work of Goodman, Blaner and collaborators has defined kemic cells. Interestingly, induction of differentiation in the biosynthesis of RBP in liver cells and its association with promyelocytes and consequent remission of APL following trans-thyretin (55 kDa) (1), which minimizes RBP loss by retinoid therapy depends on expression of a chimeric PMLglomerular filtration. Blomhoff and collaborators have illus-RARα fusion protein resulting from a t(15;17) chromosomal trated the complexity of intra-and extrahepatic transport of translocation. This protein functions as a dominant negative RBP and defined the multiplicity of compartments involved against the function of both PML and RARs and its in RBP exchange (2, 3) . Different views are presently held to overexpression is able to recreate the phenotypes of the explain retinol delivery from RBP to tissue target cells. Two disease in transgenic mice. The development of new, more camps presently favor either non-receptor-mediated passive effective and less toxic retinoids, alone or in combination diffusion (4) or RBP-receptor-mediated retinol delivery (5) . with other drugs, may provide additional avenues for cancer chemoprevention and differentiation therapy.
In addition to plasma RBP, cellular retinoid-binding proteins have been characterized. The pioneering work of Ong et al. (6) has shown that retinol and RA specifically interact with cellular retinol-binding (CRBP and CRBP II) and retinoic Abbreviations: AHR, aryl hydrocarbon receptor; APL, acute promyelocytic acid-binding (CRABP I and II) proteins. These proteins appear leukemia; ATRA, all-trans-retinoic acid; BCC, basal cell carcinoma; CBP, to mediate biological activity and/or the availability of their The degradation of RA via additional oxidation steps catalyzed by cytochromes P450 is also shown. The figure highlights how the AHR-/-genotype causes accumulation of RA and its upstream parent retinoids. As also indicated, pre-formed retinol or RA from other cells may cross the cell membrane by free diffusion and be subject to the same enzymes. Though the emphasis is placed on the generation and disposal of RA, the key events depend on the interaction of RA and its isomers with the nuclear receptors RAR and RXR.
retinoic acid receptor (RXR). These receptors will be discussed lead to activation of downstream target genes involved in liver fibrosis found in AHR null mice, such as type II later in this review.
transglutaminase and transforming growth factor β, whose expression is controlled by RA (15, 16) and both of which are Retinoid metabolism and the aryl hydrocarbon receptor (AHR) overexpressed in AHR-/-liver.
A schematic representation of the metabolic pathway of Retinoic acid and maintenance of normal differentiation retinoids is shown in Figure 1 . Excellent reviews of retinoid Pioneering efforts (17) have defined the essential function of metabolism have been published (7) (8) (9) . Here we give particular vitamin A in maintenance of normal adult epithelial differentiattention to the pivotal role that the AHR plays in controlling ation. Deficiency of dietary vitamin A was shown to cause the degradation of RA via cytochromes P450 (CYP). AHR-/-alterations in epithelial differentiation, particularly in mucus mice were generated and reported to show some phenotypic secretory epithelia of the simple and pseudo-stratified phenoabnormalities, mainly liver fibrosis (10,11). In order to detertypes. Invariably, squamous neoplastic foci form in the epithelia mine the biochemical basis of these lesions, AHR wild-type of vitamin A-deficient animals (17-21). These foci, initially and null mouse livers were tested for their RA, retinol and comprising a few cells, eventually expand to replace normal retinyl palmitate content. All of these retinoids accumulated epithelia. Thus, vitamin A deficiency induces, at the same time, 2-to 3-fold in the livers of AHR-/-compared with ϩ/ϩ mice proliferation of squamous cells and cytostasis and eventual (12). This accumulation probably resulted from a marked shedding of mucous cells (20, 21) . It also increases the number reduction in the ability of AHR-/-liver cells to oxidize RA.
of benzo[a]pyrene-derived DNA adducts, at least in the hamster Experiments with microsomes from wild-type and AHR-/-respiratory epithelium (22). Administration of RA replaces livers clearly showed a marked reduction in RA oxidation in squamous metaplastic cells by mucus-secreting cells and, thus, the AHR-/-mice. The involvement of CYPRAI (13, 14) , a re-establishes normal epithelial function. These phenotypic novel P450 active in RA 4-hydroxylation, was tested, but the alterations result from profound changes in gene expression, AHR-/-genotype did not show any effect on its expression, including keratin genes (for a recent comprehensive review at least at the mRNA level.
see ref. 20) . Since squamous metaplasia is also invariably Moreover, increased RA levels could cause a down-regulaobserved as a result of carcinogen exposure in mucous epithelia tion of RA-synthesizing enzymes. In this regard, our data and excess retinoids either reverse or prevent this lesion (23), showed that livers from AHR null mice express AHD2 mRNA the concept that retinoids may be general chemopreventive to a lesser extent (15-20%) than controls; interestingly, a direct agents against epithelial cancer has received much attention involvement of AHR in AHD expression has been excluded (24) . because AHD2 transcripts were not up-regulated upon 2,3,7,8-tetrachlorodibenzo-p-dioxin treatment in either AHR-/-or Chemoprevention ϩ/ϩ strains (12). In view of these results, AHR status becomes fundamental in liver retinoid homeostasis (Figure 1 ). The
Chemoprevention research emphasizes the concept that retinoids, when available optimally or even at supra-physiological observed large increase in retinyl esters and RA could also levels, inhibit the development of epithelial carcinogenesis, Retinoids as chemopreventive agents of breast carcinogenesis i.e. their action is exerted during the carcinogenesis process Excellent reviews of this subject have been published (24) . Comprehensive reviews of preclinical and clinical work (25, 26, 29, 30, 42, 43) and only relatively new advances in chemhave been published (25-30) and cover most organ sites in oprevention of breast cancer in animal models will be detail, including lung, cervix, intestine, prostate and bladder. covered here. This review highlights chemoprevention by retinoids in animal
The potential for hepatic toxicity of large doses of naturally models of skin and breast carcinogenesis.
occurring retinoids has inspired the search for synthetic analogs with greater chemopreventive potential and less toxicity. NRetinoids as chemopreventive agents of epidermal carcino-(4-hydroxyphenyl)retinamide (4-HPR) was shown to be an genesis effective retinoid for inhibition of breast carcinogenesis in Retinoids have been used extensively as chemopreventive rats by N-nitroso-N-methylurea (NMU) (44). 4-HPR did not agents for skin carcinogenesis (31) . The two-stage system, accumulate in the liver and therefore caused little hepatic which utilizes one application of the carcinogen 7,12-dimethyltoxicity in animals (44). Furthermore, 4-HPR accumulates in benzanthracene (DMBA) and multiple applications of a tumor the mammary gland (45) and is metabolized by mammary promoting agent, e.g. 12-O-tetradecanoylphorbol-13-acetate epithelial cells in both rodents (46) and humans (47) . Efficacy (TPA) (32), has been most studied (31) .
of 4-HPR is limited to pre-menopausal women with stage I Carcinogenesis develops as a stepwise process with the breast cancer to prevent contralateral new primaries (48) (49) (50) (51) . formation initially of benign tumors (papillomas) and later of For a more extensive discussion of the importance of the malignant tumors (carcinomas). However, this process can be timing of retinoid treatment in animal studies and additional subdivided into additional stages of premalignant progression, experimental design issues with relevance to the clinical setting malignant conversion and malignant progression. When mezersee Moon et al. (24) , Moon and Constantinou (43) and ein is used as the promoting agent, the papillomas formed are Moon (52) . at a higher risk of malignant conversion (31-33) compared
The synthetic RXR-selective ligand LDD1069 (Targretin) binds tightly to the three RXRs (α, β and γ), but has essentially with papillomas obtained through the DMBA/TPA system. no affinity for the RARs and does not appear to transactivate These mezerein-promoted papillomas are also inhibited by RA-responsive genes (53,54). After it was shown that 9-cisdietary as well as topical RA, in contrast to the low risk RA (an agonist for all six retinoid receptors or for both retinoid papillomas obtained with the DMBA/TPA protocol, which do and rexinoid receptors) prevented mammary carcinogenesis not show significant inhibition by dietary RA (34), though (55), Targretin was also tested in rats and found to prevent they are inhibited by topical RA (35) . These studies are among mammary carcinogenesis, notably without the classic pattern the few in which semi-purified diets have been used, i.e. of retinoid toxicity (e.g. mucocutaneous toxicity, headaches without other retinoids or carotenoids which complicate interand hypertriglyceridemia) seen with other retinoids (53). Addipretation of the results.
tionally, the maximum inhibition in tumor incidence and The inhibitory action of RA on skin carcinogenesis appears multiplicity with Targretin was similar to that achieved with to be exerted at the level of RARs. In situ hybridization tamoxifen (53). Although Targretin was not shown to alter analysis has shown that mouse epidermal neoplastic cells lose estrogen, progesterone or prolactin levels in this model, it the ability to express RAR transcripts during tumor promotion inhibited both estrogen-and tamoxifen-induced growth stimuand malignant progression (31, 36) . In particular, RARα lation of the uterus (53). The possibility that Targretin, in transcripts are expressed in epidermis, papillomas and differencombination therapy with tamoxifen, may prevent the unwanted tiated carcinomas, but are not expressed in undifferentiated side-effects of tamoxifen agonism in the uterus should be carcinomas and in the most malignant spindle cell carcinomas further explored. The mechanism of action for inhibition of (36) . RARγ transcripts are abundant in epidermis and papil-NMU-induced tumors by Targretin is unknown. Gottardis et al. lomas, but are absent in both differentiated and undifferentiated (53) hypothesized that Targretin may suppress the formation carcinomas and in the more malignant spindle cell carcinomas of breast tumors by several possible mechanisms, which may (36) . RARβ transcripts are absent from the epidermis (37) . In involve one of the following: (i) directly activating RXRcontrast to the reduction in RARα and γ during malignant specific pathways; (ii) enhancing activity of the endogenous progression, RXR transcript expression remains at a high level retinoids that activate the RARs; (iii) weakly activating RAR in proliferating cells in normal epidermis and tumor tissue (36) . signaling pathways. In additional experiments, these same In vitro studies of mouse epidermal keratinocyte transformainvestigators examined the ability of Targretin to induce tion by the oncogene Ha-ras demonstrated a similar RAR regression in established tumors (56). At the highest dose transcript reduction with concomitant increased proliferation. studied, Targretin induced complete regression in 72% of RARγ gene expression in ras-transformed mouse keratinocytes NMU-induced rat primary tumors. In contrast, tamoxifen, at caused RA-induced inhibition of cell growth (38) . Exposure the highest dose studied, completely inhibited growth in 33% of mouse skin to tumor promoters in vivo also produced a of tumors. Previously, RAR-selective ligands have failed to reduction in receptor transcript expression (38) .
show effectiveness in regressing established tumors in this We suggest that the mechanism underlying the chemoprevenmodel. Additionally, using a moderately effective dose of tive effects of supra-physiological RA is enhanced expression Targretin (10 mg/kg) in combination with a low dose of of RARs, which counteracts the down-regulatory effects of tamoxifen (150 µg/kg), 26% of tumors regressed completely tumor promoters (38) . This mechanism has also been proposed (56). This was a greater than additive efficacy compared with to explain the action of retinoids in chemoprevention of head either tamoxifen (5.6%) or Targretin (10.5%) alone at similar and neck cancer. The work of Lotan (39, 40) and Khuri et al. doses. This finding suggests that the mechanisms of action of (41) supports the involvement of RARβ as the mediator of Targretin and tamoxifen in tumor regression do not overlap, which may be beneficial in the clinical setting. RA action in chemoprevention of head and neck carcinogenesis.
Combination chemoprevention strategies in breast cancer
carcinogenesis than treatment with either agent alone. These encouraging experimental results have provided an impetus to chemoprevention design and implement combination chemoprevention clinical Chemoprevention by a single agent may be limited by both trials using retinoids with other agents. One example is toxicity and lack of potency. Therefore, combination chemothe combination chemoprevention trial of fenretinide and prevention strategies are currently being explored to reduce tamoxifen mentioned by Hong and Sporn in 1997 (61) . toxicity and enhance chemopreventive activity. The combinaAdditionally, given the results in complete tumor regression tion of a differentiation/anti-proliferation agent with a hormone experimental studies (56), future experimental and clinical antagonist may be beneficial and relevant in chemoprevention studies may provide information on the effectiveness of RXRof breast cancer. Estrogen is a promoting factor in mammary selective ligands (e.g. Targretin) in tandem with tamoxifen or carcinogenesis. Therefore, antagonism of the action of estrogen raloxifene. receptor α in breast tissue has been an important tool in preventing mammary carcinogenesis. Recent emphasis in Differentiation therapy of acute promyelocytic leukemia breast cancer prevention has concerned the use of agents that (APL) function as antagonists at sites where estrogen may promote carcinogenesis (i.e. breast) but maintain the beneficial agonist
Retinoic acid treatment of APL effects of estrogen at other sites (i.e. bone, brain and the Treatment which induces the differentiation of cancer cells, cardiovascular system). Both retinoid treatment and modificathus preventing further proliferation, is known as differentiation tion of hormonal status have been shown to inhibit tumors cancer therapy. The single successful example of differentiation in NMU-induced rat mammary cancer models (43, 52) . The therapy is the use of all-trans retinoic acid (ATRA), which combination of ovariectomy and retinyl acetate resulted in causes frequent remission of APL by inducing the differentisynergistic inhibition of tumor incidence and multiplicity (57).
ation of promyelocytes. APL is a fairly rare disease, making Similarly, combined ovariectomy plus 4-HPR was significantly up only 5-15% of all leukemias, and has a fairly young median more active in suppressing mammary cancer induction than age of onset, in the mid-forties (62) . Before the use of ATRA was either treatment alone (58) . In these studies 4-HPR was therapy, up to 50% of APL patients died early on during a more effective inhibitor of carcinogenesis in ovariectomized chemotherapy (63) (64) (65) (66) . Current therapy of APL includes a rats than in intact animals. This study indicated that 4-HPR is central role for ATRA treatment, which results in a dramatically highly effective in inhibiting ovarian hormone-independent improved prognosis for patients, leading to complete remission cancers and suggested that retinoid inhibition of mammary in up to 95% of patients (67) and long-term survival of around carcinogenesis may not involve an influence on ovarian hor-75% (68). These results are significant not only because of mone action. In these models, preneoplastic and/or neoplastic the real improvement in cancer survival, but also because of cell populations may display differential sensitivity to retinoids effective targeting of the therapy to the molecular lesion. and hormones (52) .
Molecular alterations in APL Investigations have been performed to determine whether
Virtually all cases of APL are associated with chromosomal the effectiveness of retinoids can be enhanced by anti-estrogens translocations involving RARα. More than 99% have a characand vice versa. The combinations 4-HPR and tamoxifen (59), teristic t(15:17)(q22;q11-21) chromosomal translocation which 9-cis-RA and tamoxifen (55), 9-cis-RA and raloxifene (60) produces a fusion protein between RARα and a protein called and Targretin and tamoxifen, as discussed above (56), have promyelocytic leukemia protein (PML) (68) . Induction of been investigated in experimental mammary carcinogenesis. maturation of promyelocytes and consequent remission of APL Following surgical excision of the first mammary carcinoma, by RA depends on the presence of the t(15:17) chromosomal the effect of treatment with 4-HPR and tamoxifen significantly translocation and resultant PML-RARα fusion protein (69) . enhanced terminal survival and reduced non-recurrent mam-PML, which was originally identified as a result of this fusion, mary cancer incidence and multiplicity in NMU-treated rats is a putative transcription factor. Several other chromosomal compared with either treatment alone (59). These results translocations occur less often in APL, resulting in fusion suggested that combination treatment with 4-HPR and tamoxof RARα with the nuclear transcription factor PLZF on ifen was superior to that of either agent alone in blocking chromosome 11 (64), the nuclear mitotic aparatus protein progression of neoplastic lesions at both early and later stages NuMa on chromosome 11 (70) and nucleophosmin on chromoof the process. The combination of 9-cis-RA with low levels some 5 (71). The resulting fusion proteins similarly include of tamoxifen was effective in mammary tumor inhibition; the DNA-binding, co-repressor, co-activator and ligand-binding addition of 9-cis-RA to a tamoxifen regimen doubled the regions of the RARα, but differ in their sensitivity to ATRA. number of animals that were tumor-free at autopsy and Leukemic cells expressing a PLZF-RARα fusion protein, in significantly diminished tumor number and tumor burden particular, do not differentiate in response to ATRA treat-(55). The authors suggested that clinical evaluation of the ment (72) . combination of 9-cis-RA and tamoxifen, either for chemo-PML-RARα expression induces APL in transgenic animals prevention or for adjuvant therapy, should be considered. The combination of 9-cis-RA and raloxifene, a synthetic estrogen
Further evidence for the importance of PML-RAR in the antagonist which does not promote growth of the uterine induction of APL is provided by transgenic models. Creation epithelium and provides desirable estrogenic activity in bone, of transgenic mice and chickens with expression of the PMLwas found to prevent more mammary tumors in NMU-induced RARα fusion protein targeted to myeloid cells reproduces rats than either agent alone (60) . Furthermore, this combination APL leukemogenesis after a long latency, demonstrating that regimen was not found to be toxic. PML-RARα is responsible for the initiation of leukemogenesis In most instances, retinoid and hormone combination chemoin humans (73) (74) (75) . In at least one example of myeloid-driven expression of PML-RARα in transgenic mice, a block in the prevention strategies resulted in greater inhibition of mammary differentiation of neutrophils occurred which could progress RXR heterodimers (90) . Additionally, PML-RARα binds RA with the same affinity as RARα and activates transcription to APL (73) . Similarly to the human disease, RA treatment induces differentiation of the leukemic cells and remission of through RAREs. In myeloid cells, PML-RARα suppresses basal level transcription by recruitment of histone deacetylase the disease in these transgenics (73) . (91, 92) but results in hyperinduction of expression of reporter Functions of the RARα genes from RAREs in the presence of RA (93) . Also consistent The RAR is important in the growth and differentiation of with the potential for a dominant negative effect of the PMLmany cell lineages, including suppression of growth and RARα fusion protein on RARα signaling, expression of induction of differentiation in myeloid cells. The RARα PML-RARα in leukemic cells is much higher than RARα belongs to a family of genes, which includes RARα and levels (94) . PML-RARα also causes redistribution of PML RARγ, each of which can generate several isofoms by alternatand RARα, with respect to subcellular localization, effects ive splicing or use of alternative promoters (76) (95) . Disruption of PML NB localization by PML-RARα availability of CBP for activation of AP-1-associated transcripis reversed following RA treatment but does not seem to be tion (77) .
responsible for differentiation of APL cells. Degradation of PML-RARα following RA treatment is due to PML-RARα-Functions of PML dependent caspase activation and cleavage of the PML portion The PML protein product is a member of the RBCC family of the fusion protein, but is not required for RA-induced of proteins and consists of a ring finger, two B boxes, a coileddifferentiation (92) . Relocation of PML to the NB, an apparent coil region and a nuclear localization sequence. PML is consequence of degradation of PML-RARα, is also not localized to both the nucleoplasm and discrete nuclear strucrequired for RA-induced differentiation of APL cells. Thus, tures called nuclear bodies (NB) or PML oncogenic domains.
RA-induced differentiation is probably mediated by release of Localization of PML to NBs appears to be modulated by its PML-RARα from transcriptional repression (92) . binding to SUMO1/PIC-1, the small ubiquitin-like modifier Current therapy of APL (78, 79) . Normal cells have 10-20 NBs which are part of the nuclear matrix and may be important in RNA transcription or RA treatment causes differentiation of APL blasts and complete chromatin function. NBs may also be important in cellular remission in Ͼ90% of patients with APL (67). In fact, antiviral defense since Herpes simplex virus type 1, adenovirus there are no reported cases of APL with the PML-RARα and human cytomegalovirus proteins target PML NBs and translocation which are not initially responsive to ATRA disrupt their structure (80) (81) (82) (83) . Additionally, the antiviral treatment. Unfortunately, complete remission is short lived in interferon induces PML expression. most patients and only 20% of patients achieve a second Transfection of PML into many different cell types supcomplete remission following ATRA alone (96) (97) (98) . The presses growth (84, 85) and induces apoptosis through both a acquired resistance to ATRA treatment may be caused by caspase-dependent and a novel caspase-independent pathway increased metabolism and clearance of RA, increased cellular (86, 87) . Recent experiments suggest that the effect of PML RA-binding protein (CRABP) levels resulting in increased on growth may be modulated by its activity as a transcription removal of PML-RARα or selection of non-PML-RARα factor. PML is associated with the AP-1 transcriptional complex leukemic clones. and cooperates with Fos to stimulate AP-1-mediated transcripCurrent therapy of APL involves an initial treatment with tion (88) . Research with PML null mice further contributes to ATRA and chemotherapy to acheive complete remission in as the evidence of the importance of PML in carcinogenesis. many as 95% of patients and disease-free survival rates of at PML null mice exhibit increased sensitivity to chemical least 60% (68) . Several cycles of post-remission chemotherapy carcinogenesis in skin and salivary gland in addition to are also employed which results in molecular remission alterations in myeloid cell numbers (87, 89) . PML null mice (absence of RT-PCR-detectable PML-RARα expression) in also demonstrate an interaction between PML and retinoid up to 95% of patients. Some form of maintenance therapy function since retinoid-activated transcription and retinoidalso appears to be beneficial. Using this treatment,~20-30% induced myeloid growth suppression and differentiation are of patients reportedly relapse and are treated with aggressive blocked in PML null cells (87, 89) . therapy including ATRA, chemotherapy and bone marrow transplantation (68, 99) .
PML-RARα functions as a dominant negative towards PML and RARα signaling
New drugs for the treatment of APL Arsenic has also been proven effective in the treatment of PML-RARα is believed to exhibit both dominant negative effects on PML and RARα signaling and gain of function APL, probably through a mechanism separate from that of RA. A majority of patients with relapsed ATRA-resistant and effects as a chimeric transcription factor. In support of this hypothesis, PML-RARα can form homodimers as well as chemotherapy-resistant APL had complete remission following arsenic treatment (up to 0.2 mg/kg body wt/day) (100,101). heterodimers with both PML and RXRs. PML-RARα actually causes a dominant negative transcriptional repression of RARThis response was associated with apoptosis rather than differ-entiation of leukemic cells (100) . In vitro, PML-RARα relocaltissue-specific chemoprevention strategies that take advantage of receptor specificities without obvious toxicity. izes PML from NBs into microspeckles, an effect which is Steroid hormones, retinoids, vitamin D, thyroid hormone reversed by arsenic. Arsenic treatment of cells in culture results
and their receptors and their downstream signal transduction in enhanced conjugation of PML to SUMO1 (78) and PML components are a very powerful family of molecules that and PML-RARα recruitment to NBs, which is followed by control transcriptional events and differentiation. The synerdegradation of both of these proteins (102). Thus, arsenic gistic chemopreventive activity of retinoids with anti-estrogens seems to specifically target the PML portion of the fusion in preclinical studies in the breast are of great interest and protein (99, 102) , whereas RA results in differentiation of APL may result, at least partially, from effects mediated by both cells, degradation of PML-RARα by arsenic causes apoptosis the retinoid and steroid hormone receptor pathways of gene (99) . These differences may be the result of transcriptional transcription. Similarly, the activity of fenretinide (which does activation by RA, in contrast to the effect of arsenic on NB not appear to bind to retinoid receptors) (113) in preventing proteins (102). However, research with PML null cells does second primary breast cancers in premenopausal women not support the conclusion that arsenic solely targets PML and (49,50) may arise from interference by the retinoid with the PML-RARα for its effects. As 2 O 3 and an organic arsenical steroid pathways downstream of the estrogen receptor. Clinical also suppress growth in PML null cells and APL cells which studies exploring the synergistic activity of fenretinide and no longer express PML-RARα (87, 103) . Thus, the effects of tamoxifen in breast cancer chemoprevention are now in arsenic on APL cells may be mediated by multiple pathways.
progress; combinations with other agents in the steroid superWarrell et al. (104) report clinical remission of APL following family, such as vitamin D and its analogs, are also of interest. addition of the histone deacetylase inhibitor sodium phenylbu-A major concern with achieving sufficient, non-toxic levels tyrate to the ATRA treatment regimen in a single patient with of retinoids in target tissues is justified because of their high ATRA-resistant APL, suggesting that inhibition of histone affinity for multiple binding sites during absorption and their deacetylases may restore sensitivity to ATRA.
self-induced metabolism en route to target sites. Several potential strategies have been suggested to address these issues.
Conclusions
One is the use of RA metabolism-blocking agents (114) and a second is local application (e.g. aerosol formulations for the The relatively recent and remarkable surge of interest in retinoid lung) of the retinoid (115). biology followed the discovery that these agents function as
The concept that RA directly controls gene transcription regulators of gene transcription, through binding to nuclear has attracted much attention and interest from medical scientists receptors that belong to the steroid/thyroid hormone receptor and researchers interested in altering the behavior of cancer superfamily (105, 106) . A nearly direct consequence of these cells through induction of differentiation. As a consequence, findings is that, in addition to public health professionals (107), a specific form of leukemia, APL, has been shown to be highly researchers in dermatology, oncology, cell biology, molecular responsive to oral RA at pharmacological doses. The leukemic biology, reproduction, embryology, etc. (20,108) are interested cells differentiate in vivo and in vitro into granulocytes and, in vitamin A and its derivatives, the retinoids.
in the process, lose the PML-RARα transcripts typical of At least three leads from current clinical results are expected this disease to follow the natural pathway to cell aging. to impact on clinical development of retinoids in the next few Differentiation therapy may well be a more effective and less years: (i) retinoid receptor-selective agents; (ii) cross-talk toxic avenue for cancer management and eventual eradication among members of the steroid superfamily; (iii) strategies for of the malignant clone. attaining sufficient tissue levels of retinoids.
The chromosomal translocation t(15;17) directly alters a retiWe have emphasized the importance of the retinoid receptors noid receptor gene and creates a new transcript made up of a as key molecules in differentiation and the prevention of epithefusion between the PML and the RARα genes. We should keep lial carcinogenesis. In the mouse skin carcinogenesis model, in mind that we still do not understand why APL is so sensitive malignant progression is associated with down-regulation of to RA and, in fact, this sensitivity represents a paradox, since it RARαα and γ expression at the mRNA level (36, 38) . We propose is difficult to understand how RA sensitivity can be associated that pharmacological RA exerts its chemopreventive actions with a mutated RARα. It is also unclear which other retinoid through up-regulation of RARα expression. Tumor promoters, receptors are the molecular targets of RA in APL. on the other hand, have been shown to directly down-regulate Though RA is clearly an excellent differentiation agent in these receptors (38, 109) . Though RARαβ does not appear to APL, it may not eradicate the malignant clone, eventually causplay a role in epidermal carcinogenesis, since it is not normally ing relapse in some patients. This may in part be due to increased expressed in this tissue, this receptor has been shown to play a metabolism of RA in patients subject to pharmacological doses pivotal role in head and neck cancer and in lung cancer, where of the retinoid, so that lower concentrations of the retinoid may it is normally down-regulated, but is up-regulated by RA in be found in the blood after prolonged treatment, and in part to cultured tumor cells (41, 110) as well as in cervical intra-epitheresistance of some malignant clones to RA. Combined chemolial neoplasia, where it is strongly underexpressed (111) . Topical therapy and differentiation therapy may provide additional retinoid administration to oral lesions, presenting with low endoprotection. Moreover, treatment with agents that inhibit RA genous RA and RARβ transcript levels, also results in strong metabolism, such as liarozol or similar compounds, may also be up-regulation of RARβ (112) .
effective. These agents have been shown to induce differentiBecause of the known cytotoxicity of retinoids and the ation of Dunning prostate carcinoma cells (114). possibility of unwanted side-effects we have highlighted the Progress in the treatment of APL has been surprisingly rapid fact that synthetic RXR-selective agents, such as Targretin, following the discovery of the effectiveness of RA in inducing maintain efficacy with fewer side-effects than natural retinoids differentiation of APL blasts and the presence of the t(15:17) chromosomal translocation in APL. Many patients are now (53,55). These observations suggest that it is possible to design hydrocarbon receptor in the activation of transforming growth factor-beta apparently cured of this disease and new treatments such as and apoptosis. Mol. Pharmacol., 54, 313-321. arsenic hold promise for helping others (99 
